Bellevue Group AG Sells 75,528 Shares of Natera, Inc. (NASDAQ:NTRA)

Bellevue Group AG reduced its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 35.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 138,459 shares of the medical research company's stock after selling 75,528 shares during the period. Bellevue Group AG owned about 0.11% of Natera worth $17,577,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in NTRA. Itau Unibanco Holding S.A. acquired a new position in shares of Natera during the second quarter valued at about $28,000. Quarry LP grew its holdings in Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company's stock valued at $34,000 after purchasing an additional 190 shares during the period. GAMMA Investing LLC increased its holdings in Natera by 50.0% in the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company's stock worth $35,000 after acquiring an additional 108 shares during the last quarter. Covestor Ltd raised its position in shares of Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock valued at $47,000 after purchasing an additional 95 shares during the period. Finally, Brooklyn Investment Group purchased a new stake in shares of Natera during the third quarter worth $70,000. 99.90% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on NTRA shares. Morgan Stanley boosted their price objective on Natera from $132.00 to $176.00 and gave the stock an "overweight" rating in a report on Thursday, November 14th. Piper Sandler raised their target price on Natera from $150.00 to $200.00 and gave the stock an "overweight" rating in a research note on Monday, November 18th. UBS Group dropped their price target on Natera from $160.00 to $145.00 and set a "buy" rating on the stock in a research report on Friday, August 9th. The Goldman Sachs Group raised their price target on Natera from $125.00 to $140.00 and gave the company a "buy" rating in a report on Wednesday, October 16th. Finally, StockNews.com cut shares of Natera from a "hold" rating to a "sell" rating in a report on Thursday, November 14th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, Natera presently has an average rating of "Moderate Buy" and an average price target of $140.59.

Insider Buying and Selling

In other news, CEO Steven Leonard Chapman sold 5,024 shares of the firm's stock in a transaction on Monday, September 16th. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52. Following the sale, the chief executive officer now owns 195,686 shares in the company, valued at $25,141,737.28. This trade represents a 2.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Jonathan Sheena sold 2,700 shares of the business's stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $127.57, for a total transaction of $344,439.00. Following the completion of the sale, the insider now owns 284,741 shares of the company's stock, valued at approximately $36,324,409.37. The trade was a 0.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 46,503 shares of company stock valued at $6,325,804 over the last quarter. Company insiders own 7.60% of the company's stock.

Natera Trading Down 0.4 %

Shares of NASDAQ NTRA traded down $0.67 during trading on Friday, reaching $167.78. The stock had a trading volume of 470,341 shares, compared to its average volume of 1,621,756. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The company has a market cap of $22.15 billion, a P/E ratio of -95.33 and a beta of 1.53. The business's 50-day moving average price is $135.51 and its 200-day moving average price is $120.32. Natera, Inc. has a fifty-two week low of $55.56 and a fifty-two week high of $171.95.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm's quarterly revenue was up 63.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.95) earnings per share. On average, equities research analysts predict that Natera, Inc. will post -1.66 EPS for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.